Home/ Stocks/ VIVS

VivoSim Labs, Inc. Common Stock

VIVS XNAS

$0.98 +0.15 (+17.90%) ▲ 15-min delayed

Open

$1.49

High

$1.57

Low

$0.91

Volume

103.66M

Market Cap

$2.42M

About VivoSim Labs, Inc. Common Stock

VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 9 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q3 2026	$26.0K	$-2,691,000	$-1.03
Q2 2026	$28.0K	$-2,545,000	$-0.98
Q1 2026	$37.0K	$-2,843,000	$-1.14

TickerDaily Coverage

Why Is VivoSim Labs, Inc. Common Stock (VIVS) Stock Up 74.9% Today?

Penny Stocks Marcus Rivera · 3h ago

VivoSim Labs, Inc. Common Stock (VIVS) exploded 74.9% to $1.48 on massive volume Wednesday, July...

View All Coverage →

Get VIVS Alerts

Stay ahead with breaking news, price alerts, and expert analysis on VivoSim Labs, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.